NGeneBio Rights Offering Schedule Revision, All Dates Postponed Compared to Original Plan
On July 2, 2026, NGeneBio filed an amendment to its previously announced rights offering decision dated April 27, 2026, revising the timeline.
This amendment postpones the detailed schedule of the rights offering following a 3:1 reverse stock split. The record date is now July 22, subscription for existing shareholders on September 9-10, payment date on September 17, and expected listing date on October 2.
Key terms including the offering size of 7,150,000 new shares, the 25% discount rate, and the pricing method remain unchanged from the original plan.
[AI Summary]This clerical amendment solely adjusts the timeline without altering the financial terms of the rights offering, thus posing no new investment risk. However, the previously announced offering itself carries a substantial dilution of approximately 44% for existing shareholders who do not fully exercise their rights.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)